江南大学夏咏梅组研究发现灵芝多糖借助miRNA抑制肿瘤生长
药用真菌多糖如灵芝多糖 (GLPs)，可通过免疫效果抑制肿瘤细胞的增殖这一假说已被广泛研究。来自江南大学化工学院的夏咏梅教授领衔的课题组试图通过研究miRNA在经多糖处理的癌症细胞中的表达来验证这一假说，研究成果将要发表在3月刊的《Carbohydrate Polymers》杂志上。
江南大学夏咏梅组研究发现灵芝多糖借助miRNA抑制肿瘤生长
夏教授的团队采用 μParaflo® 微流体mirna芯片分析(miRNA芯片检测由联川生物承担完成)一种经抗癌菌丝体GLP处理的人类肝癌细胞(HepG2)的miRNA表达谱，发现HepG2细胞中的miRNA发生差异表达。
实验和分析结果表明，61个差异表达的miRNA中有17个miRNA的表达发生显著变化。GLP可以直接通过调控肝癌基因的表达从而抑制HepG2细胞。其中，一个新发现的miRNAmiR-3131表现出了强烈的上调(92-folds，p=0.000016)。这些miRNA在肝癌和免疫相关方面中表现为协同作用。
上述实验结果清楚地揭示，灵芝多糖是通过调控肝脏miRNAs和免疫相关miRNAs来抑制HepG2细胞。此外，除了miR-3131，发现很多4位数的miRNA参与这种多糖诱导的差异表达，只要发现它们的靶基因，它们的功能及其在多糖肿瘤治疗中的功能就将逐步显现。
原文摘要：
The polysaccharides from fermented Ganoderma lucidum mycelia induced miRNAs regulation in suppressed HepG2 cells
Jie Shena, Hyeon-soo Park, Yong-mei Xia, Gon-sup Kimb, Steve W. Cui
Medicinal mushroom polysaccharides such as Ganoderma lucidum polysaccharides (GLPs) have been commonly hypothesized to suppress tumor cells proliferation through immune effects. To verify this hypothesis through investigating comprehensive miRNA expression in polysaccharide treated cancer cells, an anticancer mycelia GLP was employed to disclose miRNA differential expression of human hepatocarcinoma cells (HepG2), by using a miRNA microarray assay based on Sanger miR-Base Release 16. The experiment and the analysis result indicates that among the 61 differential expressed miRNAs (p ≤ 0.01), 17 of them were regulated significantly. GLP can inhibit HepG2 cells directly through regulation of hepatocarcinoma genes. A newly found miR-3131 exhibited the strongest upregulation (92-folds, Log 2 = 6.53, p = 0.000016). The miRNAs responded synergistically in both hepatocarcinoma and immune-related aspects.
